Guerbet: nine-month sales up over 8%

(CercleFinance.com) - For the first nine months of 2024, medical imaging products specialist Guerbet announced sales of E620.
5m, up 8.1% on a reported basis and 9.6% at constant exchange rates (CER).

Q3 sales rose by 5.4% at constant exchange rates, driven by the Americas (+13.1%) and Asia (+8.1%), while performance in EMEA (-2.3%) was again impacted by the implementation of the new supply chain in France.

Guerbet confirms its annual targets for 2024, i.e. sales growth in excess of 9% on a like-for-like and CER basis, and a return of the restated EBITDA margin to a level higher than that achieved in 2021 (14.4%).


Copyright (c) 2024 CercleFinance.com. All rights reserved.